The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...

By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...

AstraZeneca has entered into a strategic drug discovery collaboration and licensing agreement with insitro to use artificial intelligence to identify new drug targets and develop potential treatments ...

AstraZeneca (AZN) inks up to $1.5B AI drug discovery deal with insitro to target MASH and cardiomyopathies. Read more here.

AstraZeneca partners with insitro on an AI drug discovery deal worth up to $1.86 billion targeting fatty liver disease and ...

AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its ...

AstraZeneca (AZN) signed a drug-discovery deal with AI biotech insitro on Thursday, October 15, aimed at MASH, a serious liver disease, and cardiomyopathies, a group of heart-muscle diseases. The ...

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

AstraZeneca and insitro announced on Oct. 15, 2026, a strategic drug discovery collaboration and licensing agreement that ...

AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended ...

AstraZeneca has partnered with AI biotech insitro to identify drug targets and develop potential treatments for MASH, a ...